Progressive supranuclear palsy is a rare neurodegenerative tauopathy causing postural instability, vertical gaze palsy, bradykinesia, and progressive cognitive and motor impairment.
Arvinas announced phase 1 results for ARV-102, a PROTAC degrader that achieved more than 50% LRRK2 degradation in cerebrospinal fluid of Parkinson's patients after 28 days, with no serious adverse events reported.
Researchers at the University of Toronto have discovered that progressive supranuclear palsy has distinct molecular subtypes based on tau protein distribution, opening pathways for precision medicine approaches to treat this fatal neurodegenerative disease.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07570212 |
Individualized Transcranial Magnetic Stimulation in Parkinsonian Disorders |
RECRUITING | NA |
| NCT07291687 |
tDCS as Treatment for Motor Function |
RECRUITING | NA |
| NCT06647641 |
The CurePSP Genetics Program |
RECRUITING | |
| NCT06645626 |
Utilisation of Health Services and Quality of Life in Patients With Atypical Parkinsonian Syndromes |
RECRUITING | |
| NCT06588673 |
Art Therapy in Progressive Supranuclear Palsy |
ACTIVE_NOT_RECRUITING | NA |
| NCT06529744 |
Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling |
RECRUITING | |
| NCT06501469 |
Biomarkers in Parkinsonian Syndromes |
RECRUITING | |
| NCT06490926 |
NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome |
RECRUITING | |
| NCT06355531 |
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP) |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06235775 |
Administration of GV1001 for the Treatment of Progressive Supranuclear Palsy Who Completed Study GV1001-PSP-CL2-011 |
COMPLETED | PHASE2 |
